BSPK 8-K
Bespoke Extracts, Inc. (BSPK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact name of registrant as specified in its charter) |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition
On November 12, 2025, Bespoke Extracts, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information set forth under this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits – The following exhibits are filed as part of this report:
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release, dated November 12, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Bespoke Extracts, Inc. | ||
| Date: November 19, 2025 | By: | /s/ Michael Feinsod |
| Michael Feinsod Chief Executive Officer | ||
2
Exhibit 99.1
Bespoke Extracts, Inc. Reports Third Quarter 2025 Results – The Joint Company Scales Colorado Production and Margin Leadership
AURORA, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bespoke Extracts, Inc. (OTCQB: BSPK), operating as The Joint Company, today announced record results for the quarter ended September 30, 2025 — marking its strongest operational and financial performance to date.
“We’re not chasing the market — we’re building it,” said Hunter Garth, President of Bespoke Extracts. “Our Colorado business continues to prove that disciplined execution, brand trust, and smart manufacturing can win even in a contracting cannabis market. Q3 was a turning point. We produced more pre-rolls, earned strong margins, and expanded our reach — all while holding the line on overhead costs.”
Third Quarter 2025 Highlights
| · | Record Revenue: $467,945, up 19.8% from Q2 2025 and 68.6% year-over-year. |
| · | Gross Margin: 50.0%, up 860 basis points versus the prior year, driven by material, labor, and packaging efficiencies. |
| · | Net Loss Improvement: GAAP net loss narrowed to $78,088, a 72% improvement from Q3 2024. |
| · | Record Production: 209,600 pre-rolls produced during the quarter — up 81% year-over-year. |
Management Commentary
“Our 2025 strategic plan is delivering results, with demonstrable progress on revenue growth, distribution, and branded products,” said Michael Feinsod, Bespoke Chairman and CEO. “Our flexibility to adapt to changing market conditions in our core pre-roll business has allowed us to succeed this year in Colorado, setting us apart from many other participants.”
“We’ve built each of our brands brick by brick in one of the toughest cannabis markets in the country,” said Garth. “The fact that we can grow revenue by approximately 69% while expanding margins in a shrinking market says everything about our team and our process.
“This is what operational excellence looks like — continual improvement through iteration, data, and pride in the craft.”
“These Q3 results are a testament to the resilience and innovation at the core of The Joint Company,” said Michael Feinsod. “Our team's focus on efficiency and quality has not only driven record growth but also positioned us for scalable expansion. We're excited about the pipeline ahead and confident in delivering sustained value to shareholders.”
Financial Highlights
| Results of Operations | For the Three Months Ended | For the Nine Months Ended | ||||||||||||||||||||||||||||||
| September 30, 2025 | September 30, 2024 | % Change | June 30, 2025 | % Change | September 30, 2025 | September 30, 2024 | % Change | |||||||||||||||||||||||||
| Revenue | $ | 467,945 | $ | 277,471 | 68.6 | % | $ | 390,553 | 19.8 | % | $ | 1,121,657 | $ | 816,062 | 37.4 | % | ||||||||||||||||
| Gross Profit | $ | 234,175 | $ | 114,995 | 103.6 | % | $ | 197,499 | 18.6 | % | $ | 542,453 | $ | 323,693 | 67.6 | % | ||||||||||||||||
| Gross Margin | 50.0 | % | 41.4 | % | 50.6 | % | 48.4 | % | 39.7 | % | ||||||||||||||||||||||
| Operating Expenses | $ | 288,066 | $ | 377,463 | -23.7 | % | $ | 359,457 | -19.9 | % | $ | 1,003,640 | $ | 1,139,207 | -11.9 | % | ||||||||||||||||
| Net loss | $ | (78,088 | ) | $ | (275,613 | ) | -71.7 | % | $ | (205,106 | ) | -61.9 | % | $ | (543,715 | ) | $ | (850,626 | ) | -36.1 | % | |||||||||||
| Basic and diluted shares outstanding | 11,249,959 | 10,635,068 | 11,153,220 | 11,185,821 | 10,327,972 | |||||||||||||||||||||||||||
| EPS | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.02 | ) | $ | (0.05 | ) | $ | (0.08 | ) | |||||||||||||||||
Building from the Ground Up
Fourth Quarter 2025 Outlook
| · | Revenue: Projected between $425,000 and $500,000, up 41%–66% year-over-year, driven by continued demand for Fresh Joints and expansion of Doobskis and Dutch Blunts. |
| · | Gross Margin: The company expects to maintain approximately 50% blended gross margins across product lines through disciplined cost management and increased production throughput. |
| · | Innovation: Two new Company owned brands are set to launch in Q4, designed to capture adjacent market segments with highly competitive price-to-quality positioning. |
| · | Expansion: Bespoke continues to evaluate opportunities to replicate The Joint Company model in additional regulated markets, including Massachusetts and New York. |
| · | The company’s core brand, Fresh Joints, continues to lead Colorado’s pre-roll category in quality and volume growth. Meanwhile, new launches, Doobskis and Dutch Blunts gained meaningful traction with retail partners, creating diversified revenue streams and establishing The Joint Company as a multi-brand pre-roll house. |
“We’re turning a single-state success story into a scalable blueprint,” Garth added. “Our aim is simple — to control the pre-roll category through quality, efficiency, and culture. What started as a manufacturing facility in Aurora is now a system that can be replicated across markets.”
| 2 |
Bespoke Extracts, Inc.
Consolidated Balance Sheets
(Unaudited)
September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash | $ | 16,743 | $ | 60,305 | ||||
| Accounts receivable, net | 103,532 | 57,276 | ||||||
| Prepaid expense | 12,895 | 15,150 | ||||||
| Inventory, net | 63,662 | 32,526 | ||||||
| Total current assets | 196,832 | 165,257 | ||||||
| Furniture and equipment | 24,051 | 31,342 | ||||||
| License | 10,000 | 10,000 | ||||||
| Right of Use Asset | 52,690 | 140,489 | ||||||
| Deposits | 12,000 | 12,000 | ||||||
| Total assets | $ | 295,573 | $ | 359,088 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 1,392,869 | $ | 958,276 | ||||
| Note payable | 25,000 | 20,000 | ||||||
| Advances - related party | 66,872 | 66,872 | ||||||
| Operating lease liability | 52,650 | 73,523 | ||||||
| Notes payable -- secured (Net of discount of $49,810) | 335,190 | - | ||||||
| Total current liabilities | 1,872,581 | 1,118,671 | ||||||
| Long-Term liabilities | ||||||||
| Notes payable -- secured (Net of discount of $68,649) | - | 241,351 | ||||||
| Notes payable | 169,000 | 169,000 | ||||||
| Note payable - related party | 849,500 | 849,500 | ||||||
| Long-Term Operating Lease Liability | - | 72,504 | ||||||
| Total liabilities | 2,891,081 | 2,451,026 | ||||||
| Commitments and contingencies (Note 10) | ||||||||
| Stockholders' Deficit | ||||||||
| Preferred stock, par value $0.001, 50,000,000 shares authorized, 1 share issued and outstanding as of September 30, 2025 and December 31,2024, respectively | - | - | ||||||
| Series C Convertible Preferred Stock, $0.001 par value, 1 share designated; 1 share issued and outstanding as of September 30, 2025 and December 31, 2024, respectively, stated value $24,000. | - | - | ||||||
| Common stock, $0.001 par value: 3,000,000,000 authorized; 11,253,220 and 11,153,220 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 11,251 | 11,151 | ||||||
| Common stock to issue 6,478 shares | - | - | ||||||
| Additional paid-in capital | 24,341,072 | 24,301,027 | ||||||
| Accumulated deficit | (26,947,831 | ) | (26,404,116 | ) | ||||
| Total stockholders' deficit | (2,595,508 | ) | (2,091,938 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 295,573 | $ | 359,088 |
See the notes to the condensed consolidated financial statements included in the Company’s 10Q filing.
| 3 |
Bespoke Extracts, Inc.
Consolidated Statements of Operations
(Unaudited)
For the three months ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Sales | $ | 467,945 | $ | 277,471 | $ | 1,121,657 | $ | 816,062 | ||||||||
| Cost of products sold | 233,770 | 162,476 | 579,204 | 492,369 | ||||||||||||
| Gross Profit | 234,175 | 114,995 | 542,453 | 323,693 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative expenses | 260,228 | 361,393 | 911,006 | 1,035,137 | ||||||||||||
| Professional fees | 27,838 | 16,070 | 92,634 | 104,070 | ||||||||||||
| Total operating expenses | 288,066 | 377,463 | 1,003,640 | 1,139,207 | ||||||||||||
| Loss from operations | (53,891 | ) | (262,468 | ) | (461,187 | ) | (815,514 | ) | ||||||||
| Other income / (expenses) | ||||||||||||||||
| Interest expense | (24,197 | ) | (13,145 | ) | (82,528 | ) | (35,112 | ) | ||||||||
| Total other (expense) / income | (24,197 | ) | (13,145 | ) | (82,528 | ) | (35,112 | ) | ||||||||
| Loss before income tax | (78,088 | ) | (275,613 | ) | (543,715 | ) | (850,626 | ) | ||||||||
| Provision for income tax | - | - | - | - | ||||||||||||
| Net Loss | $ | (78,088 | ) | $ | (275,613 | ) | $ | (543,715 | ) | $ | (850,626 | ) | ||||
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | ||||||||||||||||
| Basic and Diluted | 11,249,959 | 10,635,068 | 11,185,821 | 10,327,972 | ||||||||||||
| NET LOSS PER COMMON SHARE OUTSTANDING | ||||||||||||||||
| Basic and Diluted | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.05 | ) | $ | (0.08 | ) | ||||
See the notes to the condensed consolidated financial statements included in the Company’s 10Q filing.
| 4 |
About Bespoke Extracts, Inc.
Bespoke Extracts, Inc. (OTCQB: BSPK) is a Nevada corporation operating through its wholly-owned subsidiary, Bespoke Extracts Colorado, LLC. The company develops and manufactures branded and white-label cannabis products for the regulated U.S. market. Its flagship platform, The Joint Company, produces pre-rolls and infused products distributed across licensed Colorado dispensaries. The company currently manufactures under its owned brands FreshJoints, Doobskis, DutchBlunts and Sweet Joints.
For more information, visit: www.bespokeextracts.com
Email: [email protected]
Forward-Looking Statement
This release contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially from those expressed due to market conditions, regulatory changes, and other risks described in Bespoke’s filings with the SEC. The company undertakes no obligation to update forward-looking statements, except as required by law.
5